California Institute of Technology

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology

Retrieved on: 
Thursday, January 12, 2023

He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.

Key Points: 
  • He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.
  • His experience with ground-breaking research is vital to the evolution of our predictive models and goal to discover more effective cancer therapies,” said Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board.
  • Predictive Oncology is changing the landscape of oncology drug discovery with a new category that goes beyond artificial intelligence.
  • In addition to his role as head of Computational Biology Department at CMU, Dr. Murphy has also served as Professor of Biological Sciences, Biomedical Engineering, and Machine Learning there.

Kikka Sushi, Partner to Whole Foods Markets, Announces the Launch of Its Plant-based Product Line, Vegan by Kikka

Retrieved on: 
Monday, January 23, 2023

Kikka Sushi, a leading partner of Whole Foods Markets for over 30 years, is proud to announce the launch of Vegan Salmon and Tuna Sushi!

Key Points: 
  • Kikka Sushi, a leading partner of Whole Foods Markets for over 30 years, is proud to announce the launch of Vegan Salmon and Tuna Sushi!
  • Kikka made the first investment by changing all white sugar to vegan sugar, avoiding bone char in all white rice products.
  • Now Kikka has developed a vegan fish product which will surprise and delight all of our plant-based consumers!
  • Kikka’s new vegan fish options are available in select flagship Whole Foods Markets, but all stores do have vegan options available.

IT Service Provider, Integris, Purchases Texas-Based CalTech to Build National Community Banking Vertical

Retrieved on: 
Wednesday, January 4, 2023

This marks Integris' third acquisition in less than six months, accelerating tremendous growth for the company and its national footprint.

Key Points: 
  • This marks Integris' third acquisition in less than six months, accelerating tremendous growth for the company and its national footprint.
  • Managed IT services are getting more complex and CalTech's reputation in the community banking space allows Integris to build on and expand best in class operations to build a national community banking practice," said Rashaad Bajwa, Chief Executive Officer of Integris.
  • According to Bajwa, Integris will leverage CalTech's well-established IT service delivery model for the community banking industry and use existing resources to expand it on a national stage.
  • With Integris, we will build a national community banking practice with top quality service, security, and premium offerings for new and existing clients," said Will Welch, Chief Executive Officer of CalTech.

NTT Scientists Report First Practical Application of Cyber-CIM

Retrieved on: 
Tuesday, December 20, 2022

NTT Research is funding a five-year cyber-CIM project with Tokyo Tech, which also includes work on drug discovery.

Key Points: 
  • NTT Research is funding a five-year cyber-CIM project with Tokyo Tech, which also includes work on drug discovery.
  • This is the first known practical application of the cyber-CIM.
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.
  • NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates.

NTT Research and Tokyo Tech Algorithm Enhances Performance and Scope of Coherent Ising Machine

Retrieved on: 
Tuesday, December 20, 2022

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists from the NTT Research Physics & Informatics (PHI) Lab and Tokyo Institute of Technology (Tokyo Tech) have presented a new algorithm that successfully combines amplitude control feedback and Zeeman terms to overcome inherent limits of a Coherent Ising Machine (CIM) and enhance its potential to solve a wide range of optimization problems.

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that scientists from the NTT Research Physics & Informatics (PHI) Lab and Tokyo Institute of Technology (Tokyo Tech) have presented a new algorithm that successfully combines amplitude control feedback and Zeeman terms to overcome inherent limits of a Coherent Ising Machine (CIM) and enhance its potential to solve a wide range of optimization problems.
  • This joint research between Tokyo Tech and NTT Research, published as an article in Communications Physics on June 15, 2022, grew out of a joint research agreement pairing the PHI Lab with the laboratory of Dr. Toru Aonishi.
  • (The Ising model is a mathematical abstraction of magnetic systems composed of competitively interacting spins, or angular momentums of fundamental particles.)
  • NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

Historic $50 Million Gift to Establish Stewart and Lynda Resnick Sustainability Center for Catalysis at the Technion

Retrieved on: 
Monday, December 19, 2022

HAIFA, Israel, Dec. 19, 2022 /PRNewswire/ -- The Technion-Israel Institute of Technology announced today that American philanthropists Lynda and Stewart Resnick, co-owners of California-based The Wonderful Company, have pledged, through their foundation, a $50 million gift to transform the university's research and development of sustainability and catalysis. The $50 million gift will establish the Stewart and Lynda Resnick Sustainability Center for Catalysis, designed to empower faculty and students to uncover new ways to maintain global growth while protecting the planet for future generations. The pledge is the latest in a series of gifts by the Resnicks' foundation to improve the quality of life of future generations by protecting the ecosystem and preserving natural resources. The Center's activity will strengthen the State of Israel and its economy and bolster the Technion's position as a global center of innovation. It will facilitate the recruitment of young scientists and promote research collaborations with academia and industry.

Key Points: 
  • The $50 million gift will establish the Stewart and Lynda Resnick Sustainability Center for Catalysis, designed to empower faculty and students to uncover new ways to maintain global growth while protecting the planet for future generations.
  • Technologies developed in the Stewart and Lynda Resnick Sustainability Center for Catalysis will enable humankind to meet its needs efficiently and speedily while lessening humans' negative impact on nature and its resources.
  • The Stewart and Lynda Resnick Sustainability Center for Catalysis will encompass a wide range of scientific expertise and enable us to meet the climate crisis and sustainable development challenges."
  • They also pledged a historic gift to fund a new agricultural innovation and research center at The University of California, Davis.

NASA Launches International Mission to Survey Earth's Water

Retrieved on: 
Friday, December 16, 2022

The Surface Water and Ocean Topography (SWOT) spacecraft also has contributions from the Canadian Space Agency (CSA) and the UK Space Agency.

Key Points: 
  • The Surface Water and Ocean Topography (SWOT) spacecraft also has contributions from the Canadian Space Agency (CSA) and the UK Space Agency.
  • The satellite will measure the height of water in freshwater bodies and the ocean on more than 90% of Earth's surface.
  • "This mission marks the continuity of 30 years of collaboration between NASA and CNES in altimetry," said Caroline Laurent, CNES Orbital Systems and Applications director.
  • "It shows how international collaboration can be achieved through a breakthrough mission that will help us better understand climate change and its effects around the world."

Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

Retrieved on: 
Thursday, December 15, 2022

LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.
  • Dr. Negrin is one of the world's leading experts in hematology and cellular immunology and joins Appia Bio's scientific founders in advising the Company's research and development.
  • "We are thrilled to have Dr. Negrin join our world-class Appia Bio Scientific Advisory Board.
  • Dr. Negrin joins Appia Bio's Scientific Advisory Board and Scientific Founders in advising the company, comprised of the following leaders in immunology, immuno-oncology, and cell therapy engineering:
    Irving Weissman, M.D., director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia & D.K.

H2U Technologies Demonstrates First-of-its-Kind Iridium-Free PEM Electrolyzer for Hydrogen Production


CHATSWORTH, Calif., Dec. 8, 2022 /PRNewswire/ -- In its strategic effort to reduce the costs of Proton Exchange Membrane (PEM) electrolyzers, H2U Technologies has demonstrated electrolyzer stacks that replace expensive and scarce iridium catalysts with inexpensive and abundant catalyst materials.

Key Points: 
  • H2U's PEM electrolyzer stacks leverage readily available catalyst materials to enable cost-effective green hydrogen generation.
  • With this successful demonstration, H2U is on track to ship its first proof-of-concept electrolyzer systems in 2023.
  • To learn more about how H2U is developing technologies that dramatically reduce the cost of green hydrogen, visit H2Utechnologies.com .
  • H2U Technologies is a developer of low-capital-cost, iridium-free proton exchange membrane (PEM) electrolyzers that are particularly suited for pairing with green energy sources.

Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors

Retrieved on: 
Thursday, December 8, 2022

THOUSAND OAKS, Calif., Dec. 8, 2022 /PRNewswire/ -- Dantari, Inc. ("Dantari"), a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, today announced its emergence from stealth mode with $47 million Series A financing. The Series A financing was led by Westlake Village BioPartners ("Westlake") and included participation from Corner Ventures, Alexandria Venture Investments, and Caltech. The Company also announced the appointment of Richard A. Markus, M.D., Ph.D., as president and chief executive officer (CEO), and its board of directors, chaired by Sean Harper, M.D., a co-founding managing director at Westlake.

Key Points: 
  • The Series A financing was led by Westlake Village BioPartners ("Westlake") and included participation from Corner Ventures, Alexandria Venture Investments, and Caltech.
  • Dantari's platform of T-HDC (Targeted High-capacity Drug Conjugate) technology enables a significantly higher drug-antibody ratio (DAR) and tunable-release of chemotherapy compared to today's ADCs.
  • The Company's lead clinical investigational product is DAN-222, a novel HDC chemotherapeutic agent with a topoisomerase 1 inhibitor (topo1) payload.
  • Dantari's proprietary T-HDC platform provides significantly enhanced capabilities for targeted delivery of therapeutics, which I believe will usher in a step-change in the treatment of solid tumors.